Friday, December 4, 2020

Kronos Bio Inc (KRON) announced it 3Q fiscal results and recent business developments

- Advertisement -
- Advertisement -

Kronos Bio, Inc. (KRON) today Nov. 18, 2020, reported recent business progress and third quarter 2020 financial results.

Recent Business progress

The Company hired Barbara Kosacz as a Chief operating officer and Dr Yasir Al-Wakeel as a Chief financial officer and head of corporate development. Elena Ridloff has been added to the company’s Board of Directors as chair of the audit committee

The Kronos Bio acquired Gilead Sciences’ portfolio of spleen tyrosine kinase (SYK) inhibitors, including entospletinib, which Kronos Bio is developing as a frontline treatment for patients with NPM1-mutated acute myeloid leukemia (AML).

In October 2020, the company earned $287.5 million (before deducting underwriting discounts and commissions and offering expenses) by completing an upsized initial public offering (IPO) of 15,131,579 of common stock.

Third Quarter Financial Highlights

For the third quarter ended September 30, 2020, cash, cash equivalents and short-term investments weretotalled at $211.3 million, excluding approximately $263.9 million in net proceeds from the company’s October 2020 upsized IPO.

The company has a net loss of $39.7 million, or $6.48 per basic and diluted share for the third quarter ended September 30, 2020, including a non-recurring $15.2 million non-cash change in fair value of convertible notes.

The company’s research and development expenses were $16.8 million for the third quarter of 2020, which includes $0.2 million in stock-based compensation expense.For the reported quarter, the company’s general and administrative expenses were $4.1 million including $1.0 million in stock-based compensation expense.

- Advertisement -

Latest news

Some Wall Street Gainers In Thursday Trading

On Thursday, after a bout of weakness at the opening, Snowflake Inc (SNOW) jumped 16.13% to $339.89 to conclude the session. Following the IPO,...
- Advertisement -

Oragenics, Inc. (OGEN) Updates on its potential COVID-19 Vaccine, expects to file an IND in 2021

The biotechnology firm is developing its vaccine candidate against SARS-CoV-2. Oragenics anticipate the Phase 1 trial of TerraCoV2 beginning in mid-2021 following the approval...

Apple (AAPL), UnitedHealth (UNH), Exxon (XOM) Surged While Salesforce (CRM) Dropped

Apple Inc’s (AAPL) shares rose 3.08 percent to $122.72 on Tuesday. Jeff Bezos' Amazon group will also use its cloud infrastructure software to manage...

U.S. Indices Marked Record High In November, Slightly Retreated On Monday

The primary U.S. stock indices ended trading in negative territory on Monday, November 30, rectifying the development observed a week earlier. The November dynamics of...

Related news

Some Wall Street Gainers In Thursday Trading

On Thursday, after a bout of weakness at the opening, Snowflake Inc (SNOW) jumped 16.13% to $339.89 to conclude the session. Following the IPO,...

Oragenics, Inc. (OGEN) Updates on its potential COVID-19 Vaccine, expects to file an IND in 2021

The biotechnology firm is developing its vaccine candidate against SARS-CoV-2. Oragenics anticipate the Phase 1 trial of TerraCoV2 beginning in mid-2021 following the approval...

Apple (AAPL), UnitedHealth (UNH), Exxon (XOM) Surged While Salesforce (CRM) Dropped

Apple Inc’s (AAPL) shares rose 3.08 percent to $122.72 on Tuesday. Jeff Bezos' Amazon group will also use its cloud infrastructure software to manage...

U.S. Indices Marked Record High In November, Slightly Retreated On Monday

The primary U.S. stock indices ended trading in negative territory on Monday, November 30, rectifying the development observed a week earlier. The November dynamics of...
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here